nach oben

International Journal of Clinical Oncology

Erschienen in:

01.06.2014 | Review Article

Update of molecular pathobiology in oral cancer: a review

verfasst von: Tomonori Sasahira, Tadaaki Kirita, Hiroki Kuniyasu

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Head and neck cancer including oral squamous cell carcinoma (OSCC) is the sixth most common cancer in the world. OSCC has a high potential for local invasion and nodal metastasis, and the overall 5-year survival rate has not significantly changed during the past 30 years. Recent research has elucidated the detailed molecular mechanisms of carcinogenesis, tumor progression, and metastasis of OSCC. It is generally accepted that OSCC arises from multiple genetic alterations caused by chronic exposure to carcinogens such as alcohol, smoking, viral infections, and inflammation. The molecular mechanisms of carcinogenesis, tumor progression, and metastasis of head and neck cancer have been elucidated by recent advances in molecular biology. However, many unsolved questions remain. In this review, we describe the current molecular biological findings such as human papillomavirus infection, epithelial–mesenchymal transition, microRNA, and our novel molecular pathological findings of OSCC.

Min R, Siyi L, Wenjun Y et al (2012) Toll-like receptor-9 agonists increase cyclin D1 expression partly through activation of activator protein-1 in human oral squamous cell carcinoma cells. Cancer Sci 103(11):1938–1945PubMedCrossRef

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29PubMedCrossRef

Tanaka S, Sobue T (2005) Comparison of oral and pharyngeal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960–2000). Jpn J Clin Oncol 35(8):488–491PubMedCrossRef

Kurihara M, Kirita T, Sasahira T et al (2013) Protumoral roles of melanoma inhibitory activity 2 in oral squamous cell carcinoma. Br J Cancer 108(7):1460–1469PubMedCentralPubMedCrossRef

Dos Reis PP, Bharadwaj RR, Machado J et al (2008) Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer 113(11):3169–3180PubMedCrossRef

Marsh D, Suchak K, Moutasim KA et al (2011) Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 223(4):470–481PubMedCrossRef

Sasahira T, Kurihara M, Bhawal UK et al (2012) Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 107(4):700–706PubMedCentralPubMedCrossRef

Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22PubMedCrossRef

Syrjanen S, Lodi G, von Bultzingslowen I et al (2011) Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 17(Suppl 1):58–72PubMedCrossRef

10.

Kreimer AR, Clifford GM, Boyle P et al (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev 14(2):467–475CrossRef

11.

D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356(19):1944–1956PubMedCrossRef

12.

Begum S, Westra WH (2008) Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol 32(7):1044–1050PubMedCrossRef

13.

Quan J, Elhousiny M, Johnson NW et al (2013) Transforming growth factor-beta1 treatment of oral cancer induces epithelial–mesenchymal transition and promotes bone invasion via enhanced activity of osteoclasts. Clin Exp Metastasis 30(5):659–670PubMedCentralPubMedCrossRef

14.

Heldin CH, Vanlandewijck M, Moustakas A (2012) Regulation of EMT by TGFbeta in cancer. FEBS Lett 586(14):1959–1970PubMedCrossRef

15.

Wu BH, Xiong XP, Jia J et al (2011) MicroRNAs: new actors in the oral cancer scene. Oral Oncol 47(5):314–319PubMedCrossRef

16.

Perez-Sayans M, Pilar GD, Barros-Angueira F et al (2012) Current trends in miRNAs and their relationship with oral squamous cell carcinoma. J Oral Pathol Med 41(6):433–443PubMedCrossRef

17.

Park NJ, Zhou H, Elashoff D et al (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15(17):5473–5477PubMedCentralPubMedCrossRef

18.

Wald AI, Hoskins EE, Wells SI et al (2011) Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck 33(4):504–512PubMedCentralPubMedCrossRef

19.

Li J, Huang H, Sun L et al (2009) MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15(12):3998–4008PubMedCrossRef

20.

Liu X, Wang A, Heidbreder CE et al (2010) MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma. FEBS Lett 584(18):4115–4120PubMedCentralPubMedCrossRef

21.

Chang KW, Liu CJ, Chu TH et al (2008) Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J Dent Res 87(11):1063–1068PubMedCrossRef

22.

Liu CJ, Tsai MM, Hung PS et al (2010) miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 70(4):1635–1644PubMedCrossRef

23.

Yu ZW, Zhong LP, Ji T et al (2010) MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 46(4):317–322PubMedCrossRef

24.

Wong TS, Liu XB, Chung-Wai Ho A et al (2008) Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 123(2):251–257PubMedCrossRef

25.

Mutallip M, Nohata N, Hanazawa T et al (2011) Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133alpha in head and neck squamous cell carcinoma (HNSCC). Int J Mol Med 27(3):345–352PubMed

26.

Jiang L, Liu X, Chen Z et al (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432(1):199–205PubMedCentralPubMedCrossRef

27.

Liu X, Wang C, Chen Z et al (2011) MicroRNA-138 suppresses epithelial–mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 440(1):23–31PubMedCentralPubMedCrossRef

28.

Zidar N, Bostjancic E, Gale N et al (2011) Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck–hallmark of epithelial–mesenchymal transition. Hum Pathol 42(4):482–488PubMedCrossRef

29.

Hatakeyama H, Cheng H, Wirth P et al (2010) Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5(9):e12702. doi:10.1371/journal.pone.0012702 PubMedCentralPubMedCrossRef

30.

Donnem T, Fenton CG, Lonvik K et al (2012) MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One 7(1):e29671. doi:10.1371/journal.pone.0029671 PubMedCentralPubMedCrossRef

31.

Slaby O, Redova M, Poprach A et al (2012) Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosom Cancer 51(7):707–716PubMedCrossRef

32.

Jiao LR, Frampton AE, Jacob J et al (2012) MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One 7(2):e32068. doi:10.1371/journal.pone.0032068 PubMedCentralPubMedCrossRef

33.

Sasahira T, Ueda N, Yamamoto K et al (2013) Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma. Clin Exp Metastasis 30(2):165–176PubMedCrossRef

34.

Sasahira T, Ueda N, Kurihara M et al (2013) Tropomyosin receptor kinases B and C are tumor progressive and metastatic marker in colorectal carcinoma. Hum Pathol 44(6):1098–1106PubMedCrossRef

35.

Davidson B, Reich R, Lazarovici P et al (2003) Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 9(6):2248–2259PubMed

36.

Yu X, Liu L, Cai B et al (2008) Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci 99(3):543–552PubMedCrossRef

37.

Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C et al (2010) Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J Clin Invest 120(3):850–858PubMedCentralPubMedCrossRef

38.

Nakagawara A, Arima-Nakagawara M, Scavarda NJ et al (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328(12):847–854PubMedCrossRef

39.

Yamashiro DJ, Liu XG, Lee CP et al (1997) Expression and function of Trk-C in favourable human neuroblastomas. Eur J Cancer 33(12):2054–2057PubMedCrossRef

40.

Satoh F, Mimata H, Nomura T et al (2001) Autocrine expression of neurotrophins and their receptors in prostate cancer. Int J Urol 8(7):S28–S34PubMedCrossRef

41.

Chuang LS, Ito K, Ito Y (2013) RUNX family: regulation and diversification of roles through interacting proteins. Int J Cancer 132(6):1260–1271PubMedCrossRef

42.

Sasahira T, Kurihara M, Yamamoto K et al (2011) Downregulation of runt-related transcription factor 3 associated with poor prognosis of adenoid cystic and mucoepidermoid carcinomas of the salivary gland. Cancer Sci 102(2):492–497PubMedCrossRef

43.

Sasahira T, Akama Y, Fujii K et al (2005) Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 446(4):411–415PubMedCrossRef

44.

Kusume A, Sasahira T, Luo Y et al (2009) Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76(4):155–162PubMedCrossRef

45.

Kuniyasu H, Sasaki T, Sasahira T et al (2004) Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 71(3):129–136PubMedCrossRef

46.

Sasahira T, Sasaki T, Kuniyasu H (2005) Interleukin-15 and transforming growth factor alpha are associated with depletion of tumor-associated macrophages in colon cancer. J Exp Clin Cancer Res 24(1):69–74PubMed

47.

Rauvala H, Huttunen HJ, Fages C et al (2000) Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 19(5):377–387PubMedCrossRef

48.

Taguchi A, Blood DC, del Toro G et al (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405(6784):354–360PubMedCrossRef

49.

Kuniyasu H, Oue N, Wakikawa A et al (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196(2):163–170PubMedCrossRef

50.

Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10(2):445–448PubMed

51.

Sasahira T, Kirita T, Bhawal UK et al (2007) Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 51(2):166–172PubMedCrossRef

52.

Sasahira T, Kirita T, Bhawal UK et al (2007) The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 450(3):287–295PubMedCrossRef

53.

Yamamoto K, Kitayama W, Denda A et al (2006) Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac. Pathobiology 73(6):317–324PubMedCrossRef

54.

Bosserhoff AK, Moser M, Buettner R (2004) Characterization and expression pattern of the novel MIA homolog TANGO. Gene Expr Patterns 4(4):473–479PubMedCrossRef

55.

Bosserhoff AK, Buettner R (2002) Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol 17(1):289–300PubMed

56.

Arndt S, Bosserhoff AK (2006) TANGO is a tumor suppressor of malignant melanoma. Int J Cancer 119(12):2812–2820PubMedCrossRef

57.

Arndt S, Bosserhoff AK (2007) Reduced expression of TANGO in colon and hepatocellular carcinomas. Oncol Rep 18(4):885–891PubMed

58.

Koehler MR, Bosserhoff A, von Beust G et al (1996) Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32–q13.33 by fluorescence in situ hybridization (FISH). Genomics 35(1):265–267PubMedCrossRef

59.

Bosserhoff AK, Stoll R, Sleeman JP et al (2003) Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest 83(11):1583–1594PubMedCrossRef

60.

Jachimczak P, Apfel R, Bosserhoff AK et al (2005) Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int J Cancer 113(1):88–92PubMedCrossRef

61.

Sasahira T, Kirita T, Oue N et al (2008) High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 99(9):1806–1812PubMed

62.

Sasahira T, Kirita T, Kurihara M et al (2010) MIA-dependent angiogenesis and lymphangiogenesis are closely associated with progression, nodal metastasis and poor prognosis in tongue squamous cell carcinoma. Eur J Cancer 46(12):2285–2294PubMedCrossRef

63.

Bosserhoff AK, Moser M, Scholmerich J et al (2003) Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes. J Biol Chem 278(17):15225–15231PubMedCrossRef

64.

Hellerbrand C, Bataille F, Schlegel J et al (2005) In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers. Liver Int 25(2):357–366PubMedCrossRef

65.

Hellerbrand C, Amann T, Schlegel J et al (2008) The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 57(2):243–251PubMedCrossRef

66.

Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95CrossRef

67.

Wu JY, Yi C, Chung HR et al (2010) Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncol 46(4):226–231PubMedCrossRef

Titel: Update of molecular pathobiology in oral cancer: a review
verfasst von: Tomonori Sasahira
Tadaaki Kirita
Hiroki Kuniyasu
Publikationsdatum: 01.06.2014
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 3/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0684-4

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Update of molecular pathobiology in oral cancer: a review

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma

Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers

Questionnaire-based survey on chemotherapy-induced anemia

Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice

NRAS mutations in primary and metastatic melanomas of Japanese patients

High incidence of regional and in-transit lymph node metastasis in patients with alveolar rhabdomyosarcoma

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie